Heilbronn, Germany's Xenios has invested $2.6 million in lung transplantation specialist Xor-Labs Toronto. Xor's Ex Vivo organ repair technology improves the quality of transplanted lungs. The company aims to reduce waiting times by expanding the number of lungs available for transplant. "The technology behind Xor's system has a long track record of clinical success. Over the past 6 years it has been used more than 200 times at UHN, approved by Health Canada, and clinical results using the technology have been extensively published, including in the prestigious New England Journal of Medicine," said Xor co-founder Dr. Shaf Keshavjee. "Xor's system will be a game-changer, since it will enable clinicians all around the world to use advanced techniques developed and perfected in Toronto, including gene and stem cell therapy, to make more lungs available for transplant and to make the transplanted lungs even better than the ones available today. All of this will improve patient care and reduce transplant waiting lists." Xenios makes devices that enable minimally invasive treatment of heart and lung failure. Release